249 related articles for article (PubMed ID: 21249679)
1. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Jan; (1):CD006647. PubMed ID: 21249679
[TBL] [Abstract][Full Text] [Related]
2. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
3. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Jan; (1):CD006647. PubMed ID: 19160293
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
[TBL] [Abstract][Full Text] [Related]
7. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
10. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
12. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
13. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
14. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003917. PubMed ID: 18425895
[TBL] [Abstract][Full Text] [Related]
16. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
17. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD003917. PubMed ID: 21678342
[TBL] [Abstract][Full Text] [Related]
19. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
20. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
